Clobazam stiripentol

After the addition of stiripentol (50 mg/kg) in 20 children treated with clobazam, mean serum clobazam concentrations increased about twofold and norclobazam concentrations increased about threefold a mean 25% reduction in clobazam dose was required because of adverse effects (15). Serum concentrations of concomitantly administered valproic acid rose by about 20%. These findings are in agreement with evidence that stiripentol is a potent metabolic inhibitor. 

Rey E, Tran A, D Athis P, Chiron C, Dulac O, Vincent J, Pons G. Stiripentol potentiates clobazam in childhood epilepsy a pharmacological study. Epilepsia 1999 40(Suppl 7) 112-3. 

Stiripentol was given marketing authorization in the European Union on 4 January 2007 for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (Dravet s syndrome) whose seizures are not adequately controlled with clobazam and valproate [284 ]. 

Drag-drag interactions Care must be taken in using stiripentol as add-on therapy with carbamazepine, clobazam, pheno-barbital, phenytoin, and valproate, because stiripentol inhibits the metabolism of these drugs and/or their metabolites [286 ]. 

---